FM
fazen.markets
healthcare·esfritzh

Scienture Q3 2026 Revenue Jumps 265% on REZENOPY Launch

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

scienture-holdingsscnx-stockrezenopy-launcharbli-losartanpharma-earnings

Key Takeaways

  • 1Scienture's second product launch tripled sequential revenue, but profitability still depends on whether clinic and government channels convert.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scienture Holdings, Inc. (NASDAQ: SCNX) reported third-quarter 2026 revenue of $1.25 million on 16 November 2026, roughly 265% above the $343,639 booked in the second quarter and about 113% higher than the $590,050 recorded a year earlier. The company said initial wholesale shipments of REZENOPY, its naloxone hydrochloride nasal spray launched in August 2026, contributed approximately $925,000 of net product revenue during the quarter.

Context — why the REZENOPY launch matters now

The quarter marks the first period in which Scienture booked revenue from two FDA-approved products rather than one. Arbli, a liquid losartan suspension, has carried the commercial story since its launch, generating approximately $330,000 in the third quarter and $730,000 across the first nine months of 2026. REZENOPY arrived in August and immediately became the larger of the two lines.

The company had already flagged the trajectory. On 13 October 2026 it issued a preliminary estimate of approximately $1.22 million for the quarter, and the final figure came in slightly above that mark. The report did not disclose the size of the October-to-November revision beyond describing it as an exceedance.

What changed the revenue mix was timing. REZENOPY's commercial availability in August meant only two months of the quarter carried its shipments, and those shipments were wholesale rather than direct-to-clinic. Scienture said it fulfilled its first orders through a dedicated direct customer channel after the quarter closed, a distribution route the company secured in September through an exclusive sales, marketing and distribution agreement targeting opioid treatment program clinics and addiction treatment centers.

The company said that agreement provides access to an established network of approximately 2,000 treatment facilities. That channel sits outside traditional wholesale distribution and did not contribute to the third-quarter revenue figure.

Data — what the numbers show

Gross profit rose to $1.02 million in the third quarter, up approximately 77.5% from $574,621 a year earlier, with a gross margin of roughly 81.3%. Across the first nine months of 2026, revenue reached $1.65 million against $600,308 in the prior-year period, an increase of approximately 176%, while nine-month gross profit rose approximately 145% to $1.41 million at an 85.2% margin.

The margin compression between the nine-month figure and the third quarter reflects the arrival of REZENOPY into the revenue mix, which the company said carried a different cost profile than Arbli.

MetricQ3 2025Q3 2026
Revenue$590,050$1.25 million
Gross profit$574,621$1.02 million
Operating loss~$4.4 million~$5.7 million
Net loss~$3.6 million~$6.0 million

The bottom line moved the other way. Third-quarter operating loss widened to approximately $5.7 million from approximately $4.4 million, and net loss reached approximately $6.0 million against approximately $3.6 million a year earlier. The company attributed the wider loss to approximately $0.8 million of FDA fees and an approximately $0.8 million licensing milestone tied to REZENOPY, plus higher research and development spending on its pipeline.

The prior-year quarter also benefited from a non-cash gain of approximately $2.4 million tied to a change in the fair value of a derivative liability, which the company said flattered that comparison.

Analysis — what it means for markets and sectors

Scienture's two products sit in unrelated therapeutic categories, and that shapes the risk profile. Arbli competes in the antihypertensive space, where the company said it secured formulary placements at more than ten U.S. pediatric hospitals and academic medical centers and reported a 74% sequential increase in wholesale unit sales. REZENOPY competes in opioid overdose reversal, a category where the company said its 10 mg nasal spray is the highest-dose FDA-approved naloxone product available in the United States.

The direct-to-clinic agreement matters more than its revenue contribution so far. Institutional buyers in addiction treatment typically purchase through group purchasing organizations or state contracts rather than retail pharmacy channels, so a clinic network gives Scienture a route that wholesale distributors do not cover. The company said it is pursuing additional distribution relationships, particularly in government markets, and flagged expansion of CMS coverage and formulary access into State Medicaid Preferred Drug Lists as priorities.

Those government channels carry longer sales cycles and contract-based pricing. The company did not disclose pricing terms, contract durations or expected volumes for either the clinic agreement or any pending government discussions.

The counter-argument sits in the cash position. Scienture ended the quarter with approximately $7.8 million in cash, cash equivalents and restricted cash, against a nine-month net loss of $12.2 million. Restricted cash of $3.03 million is not freely available, leaving roughly $4.75 million in unrestricted cash and equivalents on the balance sheet. Revenue is scaling from a small base; the loss is not.

Per-share figures reflect a 1-for-25 reverse stock split effective 5 October 2026. Nine-month net loss per common share improved to $7.70 from $23.46, and third-quarter loss per share improved to $3.76 from $4.76, though the split distorts any direct comparison with prior reported per-share figures.

Outlook — what to watch next

Scienture's management said it believes the business is positioned to reach breakeven operating income of $6 million and be profitable in 2027, based on the current sales run rate and expected growth in net product revenue. That is a company expectation, not a reported result, and it depends on the commercial ramp continuing.

The near-term catalysts are the direct customer channel and government contracting. The company said it fulfilled and shipped its first REZENOPY orders through the direct channel after the quarter closed, so the fourth-quarter report is the first that will show whether clinic-network demand converts at scale. Management also listed State Medicaid Preferred Drug List access and federal and state agency purchase contracts as active objectives.

On the Arbli side, the company said it expects retail and long-term care adoption to grow on the back of expanded CMS and commercial coverage already obtained.

Frequently Asked Questions

How much of Scienture's Q3 revenue came from REZENOPY?

Approximately $925,000 of the $1.25 million in third-quarter net product revenue came from initial wholesale shipments of REZENOPY, which became commercially available in August 2026. Arbli contributed approximately $330,000. The two figures together account for the full quarter, as Scienture said third-quarter revenue consisted entirely of net product sales of its two FDA-approved products.

Why did Scienture's net loss widen while revenue grew?

The company cited approximately $0.8 million of FDA fees and an approximately $0.8 million licensing milestone for REZENOPY, plus increased research and development investment. The prior-year quarter also included a non-cash gain of approximately $2.4 million from a change in the fair value of a derivative liability, which made the year-earlier comparison look better than the underlying operations.

What is the direct customer distribution agreement Scienture signed?

In September 2026, Scienture entered an exclusive sales, marketing and distribution agreement covering opioid treatment program clinics and addiction treatment centers across the United States. The company said the arrangement provides access to a network of approximately 2,000 treatment facilities, extending REZENOPY's reach beyond wholesale distribution. Scienture fulfilled its first orders through that channel after the quarter ended.

Bottom Line

Scienture's second product launch tripled sequential revenue, but profitability still depends on whether clinic and government channels convert.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related